4//SEC Filing
Pfanzelter David J 4
Accession 0001209191-17-054171
CIK 0001006028other
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 6:17 PM ET
Size
12.5 KB
Accession
0001209191-17-054171
Insider Transaction Report
Form 4
Pfanzelter David J
Director
Transactions
- Disposition to Issuer
Warrant
2017-09-25−16,000→ 0 totalExercise: $0.75From: 2014-07-02Exp: 2019-07-02→ Common Stock (16,000 underlying) - Exercise/Conversion
Common Stock
2017-09-25$0.60/sh+16,000$9,600→ 556,000 total - Exercise/Conversion
Warrant
2017-09-25−16,000→ 0 totalExercise: $0.60From: 2014-07-02Exp: 2017-09-25→ Common Stock (16,000 underlying) - Award
Warrant
2017-09-25+16,000→ 16,000 totalExercise: $0.60From: 2014-07-02Exp: 2017-09-25→ Common Stock (16,000 underlying)
Footnotes (2)
- [F1]On September 25, 2017, the Issuer completed the initial closing of a tender offer in which the Issuer offered to amend the terms of the outstanding warrants the Issuer issued to investors participating in private placement financings the Issuer completed on August 29, 2014 (the "2014 Warrants"), on November 23, 2015 (the "2015 Warrants") and on January 23, 2017 (the "2017 Warrants"). As part of the tender offer and in order to raise funds to support its continued operations, the Issuer offered to reduce the respective exercise prices of the 2014, 2015 and 2017 Warrants if the holders agreed to exercise their Warrants in cash by September 25, 2017. The Reporting Person holds a 2014 Warrant and elected to participate in the Issuer's tender offer. As a result, the exercise price and the expiration date, among other terms, of the 2014 Warrant held by the Reporting Person were amended.
- [F2]In accordance with the terms of the Issuer's tender offer, the Reporting Person exercised his 2014 Warrant in full and in cash on September 25, 2017.
Documents
Issuer
PURE BIOSCIENCE, INC.
CIK 0001006028
Entity typeother
Related Parties
1- filerCIK 0001569467
Filing Metadata
- Form type
- 4
- Filed
- Sep 26, 8:00 PM ET
- Accepted
- Sep 27, 6:17 PM ET
- Size
- 12.5 KB